Grundläggande statistik
| CIK | 1868912 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Enfusion, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| May 1, 2025 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-40949 Enfusion, Inc.* (Exact name of registrant as specified in i |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 21, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file numbe |
|
| April 21, 2025 |
Second Amended and Restated Certificate of Incorporation of Enfusion, Inc. Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ENFUSION, inc. (a Delaware corporation) ARTICLE I The name of the corporation is Enfusion, Inc. (hereinafter called the “Corporation”). ARTICLE II The address of the Corporation’s registered office in the State of Delaware is Corporation Service Company, 251 Little Falls Drive, Wilmington, in the County of New Castle, Delaware |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 21, 2025 |
As filed with the Securities and Exchange Commission on April 21, 2025 As filed with the Securities and Exchange Commission on April 21, 2025 Registration No. |
|
| April 21, 2025 |
Second Amended and Restated Bylaws of Enfusion, Inc. Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF ENFUSION, INC. A Delaware Corporation ARTICLE I OFFICE Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be located at 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808. The name of the corporation’s registered agent at such address shall be Corporation Service Company. The reg |
|
| April 21, 2025 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on May 02, 2025, pursuant to the provisions of Rule 12d2-2 (a). |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2025 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 17, 2025 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2025 Clearwater Analytics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40838 87-1043711 (State or Other Jurisdiction of Incorporati |
|
| April 17, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2025 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2025 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 17, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Clearwater Analytics and Enfusion Announce Preliminary Results of Election by Enfusion Shareholders Regarding Form of Merger Consideration BOISE, Idaho, and CHICAGO, Illinois – April 17, 2025 — Clearwater Analytics (NYSE: CWAN) (“Clearwater”) and Enfusion, Inc. (NYSE: ENFN) (“Enfusion”) today announced the preliminary results of the elections made by Enfusion sha |
|
| April 17, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Clearwater Analytics and Enfusion Announce Preliminary Results of Election by Enfusion Shareholders Regarding Form of Merger Consideration BOISE, Idaho, and CHICAGO, Illinois – April 17, 2025 — Clearwater Analytics (NYSE: CWAN) (“Clearwater”) and Enfusion, Inc. (NYSE: ENFN) (“Enfusion”) today announced the preliminary results of the elections made by Enfusion sha |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d)of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d)of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 2, 2025 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 Clearwater Analytics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40838 87-1043711 (State or Other Jurisdiction of Incorporatio |
|
| April 2, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Clearwater Analytics and Enfusion Announce Election Deadline for Enfusion Shareholders to Elect Form of Merger Consideration BOISE, Idaho, and CHICAGO, Illinois – April 2, 2025 — Clearwater Analytics (NYSE: CWAN) (“Clearwater”) and Enfusion, Inc. (NYSE: ENFN) (“Enfusion”) today announced that the deadline for Enfusion shareholders of record to elect the form of m |
|
| April 2, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Clearwater Analytics and Enfusion Announce Election Deadline for Enfusion Shareholders to Elect Form of Merger Consideration BOISE, Idaho, and CHICAGO, Illinois – April 2, 2025 — Clearwater Analytics (NYSE: CWAN) (“Clearwater”) and Enfusion, Inc. (NYSE: ENFN) (“Enfusion”) today announced that the deadline for Enfusion shareholders of record to elect the form of m |
|
| April 2, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d)of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d)of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 31, 2025 |
SUPPLEMENT NO. 1 DATED MARCH 31, 2025 THE PROXY STATEMENT/PROSPECTUS DATED MARCH 20, 2025 425 Filed by Clearwater Analytics Holdings, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Enfusion, Inc. Registration Statement No. 333-284816 SUPPLEMENT NO. 1 DATED MARCH 31, 2025 TO THE PROXY STATEMENT/PROSPECTUS DATED MARCH 20, 2025 This Supplement No. 1 (this “Supplement |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 20, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-40949 ENFUSIO |
|
| March 3, 2025 |
Insider Trading Policy of the Registrant. Exhibit 19.1 ENFUSION, INC. INSIDER Trading POLICY This memorandum sets forth the policy of Enfusion, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the “Insider Trading Policy”) is designed to prevent insider trading and the appearance of |
|
| March 3, 2025 |
Subsidiaries of the Registrant. EXHIBIT 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization Enfusion Ltd. LLC Delaware Enfusion US 1, Inc. Delaware Enfusion US 2, Inc. Delaware Enfusion US 3, Inc. Delaware Enfusion Systems UK Ltd England and Wales Enfusion HK Limited Hong Kong Enfusion Software Limited The Republic of Ireland Enfusion Softech India Private Limited The Republic of India Enfusion (Singapore) Pte. Ltd. The Re |
|
| March 3, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 3, 2025 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Numbe |
|
| March 3, 2025 |
Enfusion Announces Fourth Quarter and Full Year 2024 Results Exhibit 99.1 Enfusion Announces Fourth Quarter and Full Year 2024 Results March 3, 2025 NEW YORK, LONDON & HONG KONG-(BUSINESS WIRE)-Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: ● |
|
| February 27, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Clearwater Analytics and Enfusion Announce Expiration of Hart-Scott-Rodino Act Waiting Period For Proposed Acquisition of Enfusion BOISE, Idaho, February 26, 2025 – Clearwater Analytics Holdings, Inc. (NYSE: CWAN) (“Clearwater” or the “Company”), a leading worldwide provider of SaaS-based investment management, accounting, reporting, and analytics solutions, and |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d)of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 27, 2025 |
Press Release of Enfusion, Inc. and Clearwater Analytics Holdings, Inc. issued on February 26, 2025. Exhibit 99.1 FOR IMMEDIATE RELEASE Clearwater Analytics and Enfusion Announce Expiration of Hart-Scott-Rodino Act Waiting Period For Proposed Acquisition of Enfusion BOISE, Idaho, February 26, 2025 – Clearwater Analytics Holdings, Inc. (NYSE: CWAN) (“Clearwater” or the “Company”), a leading worldwide provider of SaaS-based investment management, accounting, reporting, and analytics solutions, and |
|
| February 27, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d)of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| January 14, 2025 |
425 Filed by Clearwater Analytics Holdings, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Enfusion, Inc. Commission File No. 001-40949 The following is a transcript of the investor call held by Clearwater Analytics Holdings, Inc. on January 13, 2025: Operator: Ladies and gen |
|
| January 14, 2025 |
Exhibit 4 Execution Version SUPPORT AGREEMENT This Support Agreement, dated as of January 10, 2025 (this “Agreement”), is made and entered into by and between Clearwater Analytics Holdings, Inc. |
|
| January 13, 2025 |
Exhibit 2.1 EXECUTION COPY AGREEMENT AND PLAN OF MERGER by and among ENFUSION, INC., ENFUSION LTD. LLC, CLEARWATER ANALYTICS HOLDINGS, INC. POSEIDON ACQUIRER, INC. POSEIDON MERGER SUB I, INC. and POSEIDON MERGER SUB II, LLC JANUARY 10, 2025 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 Section 1.01 Definitions 2 Section 1.02 Other Defined Terms 20 Section 1.03 Other Definitional and Interpretativ |
|
| January 13, 2025 |
Exhibit 2.1 EXECUTION COPY AGREEMENT AND PLAN OF MERGER by and among ENFUSION, INC., ENFUSION LTD. LLC, CLEARWATER ANALYTICS HOLDINGS, INC. POSEIDON ACQUIRER, INC. POSEIDON MERGER SUB I, INC. and POSEIDON MERGER SUB II, LLC JANUARY 10, 2025 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 Section 1.01 Definitions 2 Section 1.02 Other Defined Terms 20 Section 1.03 Other Definitional and Interpretativ |
|
| January 13, 2025 |
Exhibit 99.1 Execution Version SUPPORT AGREEMENT This Support Agreement, dated as of January 10, 2025 (this “Agreement”), is made and entered into by and between Clearwater Analytics Holdings, Inc., a Delaware corporation (“Parent”), and [·] (“Stockholder”, and together with Parent, the “Parties”). RECITALS WHEREAS, as of the date hereof, Stockholder is the beneficial owner (as defined i |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| January 13, 2025 |
Exhibit 99.2 CONFIDENTIAL – DO NOT DISTRIBUTE Clearwater Analytics to Acquire Enfusion for $1.5 Billion Expanding its Investment Management Platform with Front-to-Back Capabilities Investor Conference Call Scheduled for Today at 8:30 a.m. ET BOISE, Idaho and CHICAGO, Illinois – January 13, 2025 – Clearwater Analytics (NYSE: CWAN) (“Clearwater”) and Enfusion, Inc. (NYSE: ENFN) (“Enfusion”) today an |
|
| January 13, 2025 |
Filed by Clearwater Analytics Holdings, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Enfusion, Inc. Commission File No. 001-40949 Date: January 13, 2025 On January 13, 2025, Clearwater Analytics Holdings, Inc. published the following posts on X and LinkedIn in connection wi |
|
| January 13, 2025 |
Exhibit 10.1 EXECUTION VERSION AMENDMENT NO. 1 TO THE TAX RECEIVABLE AGREEMENT This AMENDMENT NO. 1 TO THE TAX RECEIVABLE AGREEMENT (this “Amendment”) is dated as of January 10, 2025, and is among Enfusion, Inc., a Delaware corporation (the “Corporate Taxpayer”), and each of the undersigned parties (each, excluding Enfusion Ltd. LLC, a Delaware limited liability company (“Opco”), a “TRA Amendment |
|
| January 13, 2025 |
Exhibit 10.1 EXECUTION VERSION AMENDMENT NO. 1 TO THE TAX RECEIVABLE AGREEMENT This AMENDMENT NO. 1 TO THE TAX RECEIVABLE AGREEMENT (this “Amendment”) is dated as of January 10, 2025, and is among Enfusion, Inc., a Delaware corporation (the “Corporate Taxpayer”), and each of the undersigned parties (each, excluding Enfusion Ltd. LLC, a Delaware limited liability company (“Opco”), a “TRA Amendment |
|
| January 13, 2025 |
Filed by Clearwater Analytics Holdings, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Enfusion, Inc. Commission File No.: 001-40949 1. The following presentation was published by Clearwater Analytics Holdings, Inc. on January 13, 2025. Date: January 13, 2025 This presentation c |
|
| January 13, 2025 |
Filed by Clearwater Analytics Holdings, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Enfusion, Inc. Commission File No. 001-40949 Date: January 13, 2025 1. On January 13, 2025, Sandeep Sahai, Chief Executive Officer of the Clearwater Analytics Holdings, Inc. (the “Company”) |
|
| January 13, 2025 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Clearwater Analytics Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40838 87-1043711 (State or Other Jurisdiction of Incorpora |
|
| January 13, 2025 |
Exhibit 99.2 CONFIDENTIAL – DO NOT DISTRIBUTE Clearwater Analytics to Acquire Enfusion for $1.5 Billion Expanding its Investment Management Platform with Front-to-Back Capabilities Investor Conference Call Scheduled for Today at 8:30 a.m. ET BOISE, Idaho and CHICAGO, Illinois – January 13, 2025 – Clearwater Analytics (NYSE: CWAN) (“Clearwater”) and Enfusion, Inc. (NYSE: ENFN) (“Enfusion”) today an |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d)of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 13, 2025 |
Exhibit 99.1 Execution Version SUPPORT AGREEMENT This Support Agreement, dated as of January 10, 2025 (this “Agreement”), is made and entered into by and between Clearwater Analytics Holdings, Inc., a Delaware corporation (“Parent”), and [·] (“Stockholder”, and together with Parent, the “Parties”). RECITALS WHEREAS, as of the date hereof, Stockholder is the beneficial owner (as defined i |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d)of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 4, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2024 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Nu |
|
| November 4, 2024 |
Exhibit 99.1 ©2024 ENFUSION. ALL RIGHTS RESERVED. Enfusion 3Q 2024 Shareholder Letter November 2024 ©2024 ENFUSION. ALL RIGHTS RESERVED. Disclaimer 2 Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933 (Securities Act) and Section 2 |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| October 29, 2024 |
ENFN / Enfusion, Inc. / Malherbe Investments LLC - SC 13G/A Passive Investment SC 13G/A 1 d870440dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES AND EXCHANGE ACT OF 1934 (Amendment No. 2)* Enfusion, Inc. (Name of Issuer) Class A common stock (Title of Class of Securities) 292812104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| October 25, 2024 |
ENFN / Enfusion, Inc. / LRA Ventures, LLC - SC 13G/A Passive Investment SC 13G/A 1 d862142dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES AND EXCHANGE ACT OF 1934 (Amendment No. 3)* Enfusion, Inc. (Name of Issuer) Class A common stock (Title of Class of Securities) 292812104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| September 6, 2024 |
ENFN / Enfusion, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0089804-1sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 4)* Enfusion Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 292812104 (CUSIP Number) Edd |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2024 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Numb |
|
| August 6, 2024 |
Exhibit 99.1 PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Enfusion 2Q 2024 Shareholder Letter August 2024 PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Disclaimer 2 Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of t |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001- |
|
| August 6, 2024 |
Exhibit 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT THIS FIRST AMENDMENT (this “Amendment”) dated as of June 21, 2024 to the Credit Agreement referenced below is by and among ENFUSION LTD. LLC, a Delaware limited liability company (the “Borrower”), ENFUSION, INC., a Delaware corporation (“Parent”), the other Guarantors identified on the signature pages hereto, the Lenders identified on the signature |
|
| August 6, 2024 |
Exhibit 10.2 ENFUSION LTD. LLC AMENDMENT NO. 1 TO SEVENTH AMENDED AND RESTATED OPERATING AGREEMENT THIS AMENDMENT NO. 1 (this “Amendment”) to that certain Seventh Amended and Restated Operating Agreement of Enfusion Ltd. LLC (the “Company”), dated as of October 19, 2021 (as amended from time to time, the “Agreement”), is made and entered into as of June 10, 2024, by the Company, Enfusion, Inc., a |
|
| August 6, 2024 |
Non-Employee Director Compensation Policy, effective July 1, 2024 Exhibit 10.3 Enfusion, Inc. Non-Employee Director Compensation Policy The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Enfusion, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its su |
|
| July 25, 2024 |
Exhibit 10.1 ENFUSION, INC. EXECUTIVE SEVERANCE POLICY The Board of Directors (the “Board”) of Enfusion, Inc. (the “Company”) has determined that the Enfusion, Inc. Executive Severance Policy (this “Policy”) should be adopted to reinforce and encourage the continued attention and dedication of the Company’s Covered Executives (as defined in Section 1 hereof) to their assigned duties. Nothing in th |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 19, 2024 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Numbe |
|
| June 18, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2024 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Numbe |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2024 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Number) |
|
| May 9, 2024 |
Exhibit 99.1 PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Enfusion 1Q 2024 Shareholder Letter May 2024 PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Disclaimer 2 Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte |
|
| March 19, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2024 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Numb |
|
| March 19, 2024 |
Exhibit 99.1 Investor & Analyst Day 2024 PROPRIETARY ©2024 ENFUSION. ALL RIGHTS RESERVED. 2 Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”), including expec |
|
| March 12, 2024 |
As filed with the Securities and Exchange Commission on March 12, 2024 As filed with the Securities and Exchange Commission on March 12, 2024 Registration No. |
|
| March 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Enfusion, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registrat |
|
| March 12, 2024 |
Exhibit 10.10 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. EMPLOYMENT AGREEMENT This employment agreement, which shall include and incorporate by reference any app |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 12, 2024 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Numb |
|
| March 12, 2024 |
Item UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents Item UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 12, 2024 |
Exhibit 10.11 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. Employment Agreement This employment agreement, which shall include and incorporate by reference any app |
|
| March 12, 2024 |
Subsidiaries of the Registrant. EXHIBIT 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization Enfusion Ltd. LLC Delaware Enfusion US 1, Inc. Delaware Enfusion US 2, Inc. Delaware Enfusion US 3, Inc. Delaware Enfusion Systems UK Ltd England and Wales Enfusion HK Limited Hong Kong Enfusion Software Limited The Republic of Ireland Enfusion Softech India Private Limited The Republic of India Enfusion (Singapore) Pte. Ltd. The Re |
|
| March 12, 2024 |
Exhibit 99.1 PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. ©2023 ENFUSION. ALL RIGHTS RESERVED. Enfusion 4Q 2023 Shareholder Letter March 2024 PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Disclaimer 2 Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking wi |
|
| March 12, 2024 |
Exhibit 10.7 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]” EMPLOYMENT AGREEMENT This employment agreement, which shall include and incorporate by reference any appen |
|
| March 12, 2024 |
Exhibit 10.12 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. EMPLOYMENT AGREEMENT This employment agreement, which shall include and incorporate by reference any app |
|
| March 12, 2024 |
Exhibit10.8 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. EMPLOYMENT AGREEMENT This employment agreement, which shall include and incorporate by reference any appen |
|
| March 12, 2024 |
Compensation Recovery Policy of the Registrant. Exhibit 97 ENFUSION, INC. COMPENSATION RECOVERY POLICY Adopted as of September 21, 2023 Enfusion, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1.Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) |
|
| March 12, 2024 |
Enfusion, Inc. Non-Employee Director Compensation Policy Exhibit 10.6 Enfusion, Inc. Non-Employee Director Compensation Policy The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Enfusion, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its su |
|
| February 14, 2024 |
EX-99.1 2 tm246212d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1)(iii) of the Securities Exchange Act of 1934, as amended, each of the undersigned agree to the joint filing on behalf of each of them of the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Class A common stock, par value $0.001 per share, of Enfusion, I |
|
| February 14, 2024 |
ENFN / Enfusion, Inc. / Dragoneer Investment Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 d783102dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) * ENFUSION, INC. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 292812104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Che |
|
| February 14, 2024 |
ENFN / Enfusion, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0086869-6sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 3)* Enfusion Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 292812104 (CUSIP Number) Edd |
|
| February 14, 2024 |
ENFN / Enfusion, Inc. / ICONIQ Strategic Partners V, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d787797dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Enfusion, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 292812104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 14, 2024 |
ENFN / Enfusion, Inc. / CSL Tech Holdings LLC - SC 13G/A Passive Investment SC 13G/A 1 tm246212d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) * Enfusion, Inc. (Name of Issuer) Class A common stock, par value $0.001 per share (Title of Class of Securities) 292812104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) C |
|
| February 14, 2024 |
ENFN / Enfusion, Inc. / Werner Capital LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES AND EXCHANGE ACT OF 1934 (Amendment No. 1)* Enfusion, Inc. (Name of Issuer) Class A common stock (Title of Class of Securities) 292812104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 7, 2024 |
ENFN / Enfusion, Inc. / LRA Ventures, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES AND EXCHANGE ACT OF 1934 (Amendment No. 2)* Enfusion, Inc. (Name of Issuer) Class A common stock (Title of Class of Securities) 292812104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| January 19, 2024 |
SC 13G/A 1 ea191849-13ga1malhenfu.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES AND EXCHANGE ACT OF 1934 (Amendment No. 1)* Enfusion, Inc. (Name of Issuer) Class A common stock (Title of Class of Securities) 292812104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statemen |
|
| January 18, 2024 |
Enfusion Elevates Valeria Gutowski to Chief Accounting Officer Exhibit 99.1 Enfusion Elevates Valeria Gutowski to Chief Accounting Officer January 18, 2024 NEW YORK & LONDON & HONG KONG-(BUSINESS WIRE)- Enfusion, Inc. (“Enfusion”) (NYSE: ENFN), a leading provider of cloud-native software-as-a-service (SaaS) solutions for investment managers, today announced the internal executive promotion of Valeria Gutowski to the role of Chief Accounting Officer, effective |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 18, 2024 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Nu |
|
| November 20, 2023 |
Exhibit 99.1 Enfusion Announces Appointment of Chief Operating Officer Neal Pawar brings decades of experience as a financial services and technology leader to Enfusion, having previously served in executive and leadership roles at AQR Capital Management, D.E. Shaw, Deutsche Bank, and UBS Wealth Management November 20, 2023 New York / London / Hong Kong — Enfusion, Inc. (“Enfusion”) (NYSE: ENFN), |
|
| November 20, 2023 |
Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]” EMPLOYMENT AGREEMENT This employment agreement, which shall include and incorporate by reference any appen |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 20, 2023 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File N |
|
| November 7, 2023 |
Exhibit 99.1 PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. ©2023 ENFUSION. ALL RIGHTS RESERVED. Enfusion 3Q 2023 Shareholder Letter November 2023 PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Disclaimer 2 Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2023 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Nu |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 15, 2023 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File |
|
| September 18, 2023 |
Enfusion Announces Closing of New $100 Million Credit Facility Exhibit 99.1 Enfusion Announces Closing of New $100 Million Credit Facility September 18, 2023 New York / London / Hong Kong — Enfusion, Inc. (“Enfusion”) (NYSE: ENFN), a leading provider of cloud-native software-as-a-service (SaaS) solutions for investment managers, announced today that on September 15, 2023, it entered into a new $100 million revolving credit facility. The lenders under the cred |
|
| September 18, 2023 |
Exhibit 10.1 CREDIT AGREEMENT Dated as of September 15, 2023 among ENFUSION LTD. LLC, as the Borrower, ENFUSION, INC., as Parent, CERTAIN SUBSIDIARIES OF PARENT PARTY HERETO, as the Guarantors, BANK OF AMERICA, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, and THE LENDERS PARTY HERETO BOFA SECURITIES, INC., as Sole Lead Arranger and Sole Bookrunner TABLE OF CONTENTS Page ARTICLE |
|
| August 18, 2023 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2023 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Num |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001- |
|
| August 8, 2023 |
Exhibit 99.1 PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. ©2023 ENFUSION. ALL RIGHTS RESERVED. Enfusion 2Q 2023 Shareholder Letter August 2023 PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Disclaimer 2 Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking w |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2023 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Numb |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2023 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Numbe |
|
| June 23, 2023 |
ENFN / Enfusion Inc - Class A / FTV IV, L.P. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. )* Enfusion, Inc. (Name of Issuer) Class A common stock, par value $0.01 per share (Title of Class of Securities) |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2023 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Numbe |
|
| June 8, 2023 |
12 months ended 12/31/2022 (in thousands) June 8, 2023 VIA EDGAR David Edgar and Kathleen Collins Division of Corporation Finance Office of Technology United States Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| May 12, 2023 |
May 12, 2023 VIA EDGAR David Edgar and Kathleen Collins Division of Corporation Finance Office of Technology United States Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| May 9, 2023 |
Exhibit 99.1 PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. ©2023 ENFUSION. ALL RIGHTS RESERVED. Enfusion 1Q 2023 Shareholder Letter May 2023 PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Disclaimer 2 Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking with |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Number) |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 1, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte |
|
| April 17, 2023 |
April 17, 2023 VIA EDGAR David Edgar Division of Corporation Finance Office of Technology United States Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-40949 ENFUSIO |
|
| March 10, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Enfusion, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registrat |
|
| March 10, 2023 |
Exhibit 10.6 Enfusion, Inc. Non-Employee Director Compensation Policy The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Enfusion, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its su |
|
| March 10, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization Enfusion Ltd. LLC Delaware Enfusion US 1, Inc. Delaware Enfusion US 2, Inc. Delaware Enfusion US 3, Inc. Delaware Enfusion Systems UK Ltd England and Wales Enfusion HK Limited Hong Kong Enfusion Software Limited The Republic of Ireland Enfusion Softech India Private Limited The Republic of India Enfusion (Singapore) Pte. Ltd. The Re |
|
| March 10, 2023 |
As filed with the Securities and Exchange Commission on March 10, 2023 As filed with the Securities and Exchange Commission on March 10, 2023 Registration No. |
|
| March 9, 2023 |
ENFN / Enfusion Inc - Class A / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 2)* Enfusion Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 292812104 (CUSIP Number) Eddie C. Brown Brown Capital Managem |
|
| March 7, 2023 |
Exhibit 99.1 PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Enfusion 4Q 2022 Shareholder Letter March 2023 PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Disclaimer Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2023 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Numbe |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2023 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File N |
|
| February 14, 2023 |
ENFN / Enfusion Inc - Class A / Movchan Oleg - SC 13G/A Passive Investment SC 13G/A 1 tm236750d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) * Enfusion, Inc. (Name of Issuer) Class A common stock, par value $0.001 per share (Title of Class of Securities) 292812104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) C |
|
| February 14, 2023 |
EX-99.A 2 d386692dex99a.htm EX-99.A EXHIBIT A |
|
| February 14, 2023 |
EX-24.1 2 tm236750d1ex24-1.htm EXHIBIT 24.1 Exhibit 24.1 LIMITED POWER OF ATTORNEY The undersigned, in his or her capacity as the manager of CSL Tech Holdings, LLC, hereby constitutes and appoints each of Bradley Herring and Matthew Campobasso of Enfusion, Inc., a Delaware corporation (the “Company”), signing singly, and with full power of substitution, the undersigned’s true and lawful attorney-i |
|
| February 14, 2023 |
ENFN / Enfusion Inc - Class A / Dragoneer Investment Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 d386692dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * ENFUSION, INC. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 292812104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Che |
|
| February 14, 2023 |
EX-99.1 4 tm236750d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1)(iii) of the Securities Exchange Act of 1934, as amended, each of the undersigned agree to the joint filing on behalf of each of them of the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Class A common stock, par value $0.001 per share, of Enfusion, I |
|
| February 14, 2023 |
EX-24.2 3 tm236750d1ex24-2.htm EXHIBIT 24.2 Exhibit 24.2 LIMITED POWER OF ATTORNEY The undersigned, in his or her capacity as the managing member of Quiet Light Securities, LLC, hereby constitutes and appoints each of Bradley Herring and Matthew Campobasso of Enfusion, Inc., a Delaware corporation (the “Company”), signing singly, and with full power of substitution, the undersigned’s true and lawf |
|
| February 14, 2023 |
ENFN / Enfusion Inc - Class A / BROWN CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0081788-1sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 1)* Enfusion Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 292812104 (CUSIP Number) Edd |
|
| February 13, 2023 |
ENFN / Enfusion Inc - Class A / LRA Ventures, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES AND EXCHANGE ACT OF 1934 (Amendment No. 1)* Enfusion, Inc. (Name of Issuer) Class A common stock (Title of Class of Securities) 292812104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| January 11, 2023 |
Enfusion Names Michael Spellacy as Board Chair and Non-Executive Director Exhibit 99.1 Enfusion Names Michael Spellacy as Board Chair and Non-Executive Director January 11, 2023 New York / London / Hong Kong —Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of cloud-native software-as-a-service (SaaS) solutions for investment managers, today announced that on January 9, 2023, its Board of Directors (the “Board”) had appointed Michael Spellacy, as Board Chair |
|
| January 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2023 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Num |
|
| December 22, 2022 |
Enfusion Names Oleg Movchan as Chief Executive Officer Exhibit 99.1 Enfusion Names Oleg Movchan as Chief Executive Officer December 22, 2022 New York / London / Hong Kong ?Enfusion, Inc. (?Enfusion?) (NYSE: ENFN), a leading provider of cloud-native SaaS solutions for investment managers, today announced that its Board of Directors (the ?Board?) has appointed Oleg Movchan, as Chief Executive Officer, effective December 22, 2022. Mr. Movchan has been se |
|
| December 22, 2022 |
Employment Agreement between Oleg Movchan and Enfusion Ltd., LLC, dated December 22, 2022. Exhibit10.1 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]? EMPLOYMENT AGREEMENT This employment agreement, which shall include and incorporate by reference any append |
|
| December 22, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 22, 2022 Enfusion, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Com |
|
| December 19, 2022 |
Employment Agreement between Bradley Herring and Enfusion Ltd., LLC, dated December 14, 2022. Exhibit 10.1 Chicago 125 South Clark Street Suite 750 Chicago, IL 60603 enfusion.com EMPLOYMEN?T AGREEMEN?T This employment agreement, which shall include and incorporate by reference any appendix attached hereto, now or in the future (collectively ?Agreement?), is entered into on December R1R4, 2022, (?Effect?ive Date?), by and between ENFUSION LTD. LLC (?Enfus?ion?), with its principal place of |
|
| December 19, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 19, 2022 Enfusion, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Com |
|
| December 19, 2022 |
? Exhibit 99.1 ? Enfusion Appoints Brad Herring as New Chief Financial Officer Veteran public company CFO brings successful FinTech, SaaS, and growth stage company experience December 19, 2022 NEW YORK & LONDON & HONG KONG-(BUSINESSWIRE)-Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of cloud-native SaaS solutions for investment managers, today announced the appointment of Brad Herri |
|
| November 30, 2022 |
EX-99.1 2 enfn-20221130xex99d1.htm EX-99.1 Exhibit 99.1 Enfusion Welcomes New Addition to Board of Directors Deirdre Somers joins as new member of Enfusion’s Audit and Nominating and Corporate Governance Committees November 30, 2022 New York / London / Hong Kong —Enfusion, Inc. (NYSE: ENFN), a leading provider of cloud-native SaaS solutions for investment managers, today announced the appointment |
|
| November 30, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 30, 2022 Enfusion, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Com |
|
| November 30, 2022 |
Enfusion, Inc. 125 South Clark Street, Suite 750 Chicago, IL 60603 Enfusion, Inc. 125 South Clark Street, Suite 750 Chicago, IL 60603 VIA EDGAR November 30, 2022 ? United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Jan Woo, Legal Branch Chief Aliya Ishmukhamedova, Law Clerk ? ? Re: Enfusion, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-268477 ? Dear Ms. |
|
| November 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 23, 2022 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File N |
|
| November 28, 2022 |
EX-99.1 2 enfn-20221123xex99d1.htm EX-99.1 Exhibit 99.1 Enfusion Announces Resignation of Chief Financial Officer Reiterates 2022 Fourth Quarter and Full Year Guidance November 28, 2022 NEW YORK / LONDON / HONG KONG, November 28, 2022 – Enfusion, Inc. (“Enfusion”) (NYSE: ENFN), a leading provider of cloud-based investment management software and services, today announced that Stephen Dorton has re |
|
| November 18, 2022 |
Form of Subordinated Indenture. Exhibit 4.6 ? ? ENFUSION, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities ? ? ? ? TABLE OF CONTENTS1 ? ? ? ? Article 1 DEFINITIONS 1 ? ? ? Section 1.01 Definitions of Terms 1 ? ? ? Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 ? ? ? Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of |
|
| November 18, 2022 |
Exhibit 4.4 ? ? ENFUSION, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Senior Debt Securities ? ? ? ? TABLE OF CONTENTS1 ? ? ? Page ? ? ? ARTICLE 1 DEFINITIONS 1 ? ? ? Section 1.01 Definitions of Terms 1 ? ? ? ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 ? ? ? Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form |
|
| November 18, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLE ? Form S-3 (Form Type) ? Enfusion, Inc. |
|
| November 18, 2022 |
As filed with the Securities and Exchange Commission on November 18, 2022. S-3 1 tmb-20221118xs3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on November 18, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 87-1268462 (State or other jurisdiction |
|
| November 10, 2022 |
Enfusion Announces Third Quarter 2022 Results Exhibit 99.1 Enfusion Announces Third Quarter 2022 Results Continued Business Momentum and Strong Execution Generated Robust Financial Results November 10, 2022 NEW YORK & LONDON & HONG KONG-(BUSINESS WIRE)-Enfusion, Inc. (NYSE: ENFN), a leading provider of cloud-based investment management software and services, today announced financial results for the third quarter ended September 30, 2022. ?We |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2022 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File N |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| October 11, 2022 |
ENFN / Enfusion Inc - Class A / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 0)* Enfusion Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 292812104 (CUSIP Number) Eddie C. Brown Bro |
|
| August 22, 2022 |
Exhibit 99.1 Enfusion Appoints Oleg Movchan Interim Chief Executive Officer Reiterates 2022 Third Quarter and Full Year Revenue Guidance NEW YORK / LONDON / HONG KONG, August 22, 2022 ? Enfusion, Inc. (?Enfusion?) (NYSE: ENFN), a leading provider of cloud-based investment management software and services, today announced that its Board of Directors (the ?Board?) has appointed Oleg Movchan, current |
|
| August 22, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 21, 2022 Enfusion, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Com |
|
| August 22, 2022 |
Employment Agreement dated August 21, 2022 between the Company, Enfusion Ltd. LLC and Oleg Movchan. Exhibit 10.1 August 21, 2022 Via Email Oleg Movchan Dear Oleg: Enfusion, Ltd. LLC (?OpCo?) and Enfusion, Inc. (?PubCo? and, together with OpCo, the ?Company?), are pleased to extend you an offer of employment as Interim Chief Executive Officer of the Company (?Interim CEO?), reporting to the Board of Directors of PubCo (the ?Board?), effective August 21, 2022 (the ?Effective Date?). The terms of y |
|
| August 22, 2022 |
Separation Agreement dated August 21, 2022 between the Company and Thomas Kim. Exhibit 10.2 August 21, 2022 Thomas Kim Re:Separation Agreement Dear Thomas: This letter follows our recent discussions relating to your resignation from your employment with Enfusion, Inc. and its affiliates (the ?Company?). The last date of your employment is August 21, 2022 (the ?Separation Date?). The Company?s Board of Directors (the ?Board?) appreciates your contributions as well as your pro |
|
| August 12, 2022 |
ENFN / Enfusion Inc - Class A / Movchan Oleg - SCHEDULE 13G/A Passive Investment SC 13G/A 1 movc20220809sc13ga.htm SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) * Enfusion, Inc. (Name of Issuer) Class A common stock, par value $0.001 per share (Title of Class of Securities) 292812104 (CUSIP Number) August 12, 2022 (Date of Event Which Requires Filing of this Statem |
|
| August 12, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1)(iii) of the Securities Exchange Act of 1934, as amended, each of the undersigned agree to the joint filing on behalf of each of them of the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Class A common stock, par value $0.001 per share, of Enfusion, Inc. This Joint Filing Agreement may be execu |
|
| August 10, 2022 |
? ? Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| August 10, 2022 |
Exhibit 10.3 ? Amendment to Appendix 1 ? Scope of Employment ? This document serves as an amendment to the vacation paragraph within your most recent employment agreement appendix. The below paragraph replaces the paragraph related to vacation in its entirety. This amendment does not constitute a new employment agreement or alter any other terms of your employment with Enfusion. ? In accordance wi |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 10, 2022 |
Exhibit 10.7 Amendment to Appendix 1 ? Scope of Employment ? This document serves as an amendment to the vacation paragraph within your most recent employment agreement appendix. The below paragraph replaces the paragraph related to vacation in its entirety. This amendment does not constitute a new employment agreement or alter any other terms of your employment with Enfusion. ? In accordance with |
|
| August 10, 2022 |
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| August 10, 2022 |
Exhibit 10.4 ? Amendment to Appendix 1 ? Scope of Employment ? This document serves as an amendment to the vacation paragraph within your most recent employment agreement appendix. The below paragraph replaces the paragraph related to vacation in its entirety. This amendment does not constitute a new employment agreement or alter any other terms of your employment with Enfusion. ? In accordance wi |
|
| August 10, 2022 |
Exhibit 10.8 Amendment to Appendix 1 ? Scope of Employment This document serves as an amendment to the vacation paragraph within your most recent employment agreement appendix. The below paragraph replaces the paragraph related to vacation in its entirety. This amendment does not constitute a new employment agreement or alter any other terms of your employment with Enfusion. In accordance with Enf |
|
| August 10, 2022 |
Exhibit 10.6 ? Amendment to Appendix 1 ? Scope of Employment ? This document serves as an amendment to the vacation paragraph within your most recent employment agreement appendix. The below paragraph replaces the paragraph related to vacation in its entirety. This amendment does not constitute a new employment agreement or alter any other terms of your employment with Enfusion. ? In accordance wi |
|
| August 10, 2022 |
Exhibit 10.5 ? Amendment to Appendix 1 ? Scope of Employment ? This document serves as an amendment to the vacation paragraph within your most recent employment agreement appendix. The below paragraph replaces the paragraph related to vacation in its entirety. This amendment does not constitute a new employment agreement or alter any other terms of your employment with Enfusion. ? In accordance wi |
|
| August 9, 2022 |
Enfusion Announces Second Quarter 2022 Results EX-99.1 2 enfn-20220809xex99d1.htm EX-99.1 Exhibit 99.1 Enfusion Announces Second Quarter 2022 Results ● Revenue Grew 38% Y-o-Y Reflecting Consistent Execution and Strong Client Demand ● Exceeded Adjusted EBITDA Guidance and Generated Positive Operating Cash Flow ● Conversions Represented 75% of New Client Bookings; Bookings for New Client Conversions up 63% Y-o-Y ● Net Dollar Retention Expanded t |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2022 Enfusion, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commis |
|
| June 22, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2022 Enfusion, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commiss |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 12, 2022 |
Exhibit 99.1 ? ? Enfusion Announces First Quarter 2022 Results Revenue Up 40% Y-o-Y Driven by Strong Business Fundamentals Y-o-Y Revenue Growth in EMEA, APAC and Americas up 59%, 47%, and 35%, Respectively Record Aggregate Contract Value in New Logo Wins ? May 12, 2022 NEW YORK & LONDON & HONG KONG-(BUSINESS WIRE)-Enfusion, Inc. (?Enfusion?) (NYSE: ENFN), a leading provider of cloud-based investme |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2022 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Number |
|
| April 29, 2022 |
DEFA14A 1 tmb-20220429xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| April 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as perm |
|
| March 30, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Enfusion, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities ? CALCULATION OF REGISTRATION FEE ? 2 ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price per Share Propos |
|
| March 30, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization Enfusion Ltd. LLC Delaware Enfusion US 1, Inc. ? Delaware Enfusion US 2, Inc. ? Delaware Enfusion US 3, Inc. ? Delaware Enfusion Systems UK Ltd ? England and Wales Enfusion HK Limited ? Hong Kong Enfusion Software Limited ? The Republic of Ireland Enfusion Softech India Private Limited ? The Republic of India Enfusion (Singapore) Pt |
|
| March 30, 2022 |
Exhibit 4.3 ? DESCRIPTION OF SECURITIES As of December 31, 2021, Enfusion, Inc. (?Enfusion,? ?we,? ?our? or ?us?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act): our Class A common stock, $0.001 per share. The following descriptions are summaries of the material terms of our amended and restated certificate of incorp |
|
| March 30, 2022 |
Exhibit 4.2 ? ENFUSION, INC. REGISTRATION RIGHTS AGREEMENT OCTOBER 20, 2021 ? ? ? ? REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made as of the 20th day of October, 2021, by and among Enfusion, Inc., a Delaware corporation (the ?Company?), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an ?Investor? |
|
| March 30, 2022 |
Exhibit 10.13 SENIOR SECURED CREDIT FACILITIES AMENDED AND RESTATED CREDIT AGREEMENT dated as of October 19, 2021, among ENFUSION, INC., as Holdings, ENFUSION LTD. LLC, as Borrower, THE SEVERAL LENDERS FROM TIME TO TIME PARTY HERETO, and SILICON VALLEY BANK, as Administrative Agent, Issuing Lender and Sole Lead Arranger CITY NATIONAL BANK, as Syndication Agent and CADENCE BANK, N.A., as Documentat |
|
| March 30, 2022 |
Exhibit 10.2 ENFUSION LTD. LLC SEVENTH AMENDED AND RESTATED OPERATING AGREEMENT Dated as of October 19, 2021 THE UNITS REPRESENTED BY THIS SEVENTH AMENDED AND RESTATED OPERATING AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY OTHER APPLICABLE SECURITIES LAWS. SUCH UNITS MAY NOT BE SOLD, ASSIGNED, PLEDGED OR OTHERWISE DISPOSED OF AT ANY TI |
|
| March 30, 2022 |
As filed with the Securities and Exchange Commission on March 30, 2022 As filed with the Securities and Exchange Commission on March 30, 2022 Registration No. |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 30, 2022 |
Exhibit 10.3 ? TAX RECEIVABLE AGREEMENT ? between ? ENFUSION, INC. and THE PERSONS NAMED HEREIN Dated as of October 19, 2021 ? ? ? TABLE OF CONTENTS ? ? ? ? ? ? ? ? Page Article I DEFINITIONS ? 2 ? ? ? ? SECTION 1.1. Definitions ? 2 ? ? ? Article II DETERMINATION OF CERTAIN REALIZED TAX BENEFIT ? 11 ? ? ? ? SECTION 2.1. Basis Schedule ? 11 ? SECTION 2.2. Tax Benefit Schedule ? 11 ? SECTION 2.3. Pr |
|
| March 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 24, 2022 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Numb |
|
| March 24, 2022 |
Enfusion Announces Fourth Quarter and Full Year 2021 Results Exhibit 99.1 Enfusion Announces Fourth Quarter and Full Year 2021 Results Strong Business Momentum Drove Fourth Quarter Revenue Growth of 41% March 24, 2022 NEW YORK & LONDON & HONG KONG-(BUSINESS WIRE)-Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of cloud-based investment management software and services, today announced financial results for the fourth quarter and year ended Dece |
|
| March 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): March 1, 2022 Enfusion, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commiss |
|
| March 7, 2022 |
Enfusion Announces Tarek Hammoud’s Retirement Exhibit 99.1 ? Enfusion Announces Tarek Hammoud?s Retirement ? March 7, 2022 ? NEW YORK & LONDON & HONG KONG-(BUSINESS WIRE)-Enfusion, Inc. (?Enfusion?) (NYSE: ENFN), a leading provider of cloud-native investment management software and services, today announced that founder Tarek Hammoud is retiring and will step down as a member of Enfusion?s Board of Directors. ?Tarek has been a great partner i |
|
| February 18, 2022 |
EX-24 2 tm226458d2ex24.htm EXHIBIT 24 Exhibit 24 LIMITED POWER OF ATTORNEY The undersigned, in his or her capacity as the sole manager of LRA Ventures, LLC, hereby constitutes and appoints each of Thomas Kim, Stephen P. Dorton, and Blake Nielsen, signing singly, and with full power of substitution, the undersigned’s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersig |
|
| February 18, 2022 |
ENFN / Enfusion Inc - Class A / LRA Ventures, LLC - SC 13G Passive Investment SC 13G 1 tm226458d2sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES AND EXCHANGE ACT OF 1934 (Amendment No. )* Enfusion, Inc. (Name of Issuer) Class A common stock (Title of Class of Securities) 292812104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| February 18, 2022 |
Joint Filing Agreement, dated as of February 18, 2022. EX-99.1 3 tm226458d2ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. Th |
|
| February 16, 2022 |
ENFN / Enfusion Inc - Class A / Werner Capital LLC - SC 13G Passive Investment SC 13G 1 tm226458d3sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES AND EXCHANGE ACT OF 1934 (Amendment No. )* Enfusion, Inc. (Name of Issuer) Class A common stock (Title of Class of Securities) 292812104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| February 16, 2022 |
Joint Filing Agreement, dated as of February 16, 2022. EX-99.1 4 tm226458d3ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. Th |
|
| February 16, 2022 |
ENFN / Enfusion Inc - Class A / Malherbe Investments LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES AND EXCHANGE ACT OF 1934 (Amendment No. )* Enfusion, Inc. (Name of Issuer) Class A common stock (Title of Class of Securities) 292812104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 16, 2022 |
Joint Filing Agreement, dated as of February 16, 2022. EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be |
|
| February 16, 2022 |
Exhibit 24.1 LIMITED POWER OF ATTORNEY The undersigned, in his or her capacity as the sole manager of Werner Capital LLC, hereby constitutes and appoints each of Thomas Kim, Stephen P. Dorton, and Blake Nielsen, signing singly, and with full power of substitution, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity |
|
| February 16, 2022 |
Exhibit 24.2 LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Thomas Kim, Stephen P. Dorton, and Blake Nielsen, signing singly, and with full power of substitution, the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as officer and/or director of Enfusion, Inc., a Delaware corporatio |
|
| February 14, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT Each of the undersigned, pursuant to Rule 13d-1(k)(1) under the Act, hereby agrees and acknowledges that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the Class A Common Stock and the information required by this Schedule 13G, to which this Agreement is attached as |
|
| February 14, 2022 |
EX-99.1 2 tm226458d4ex99-1.htm EXHIBIT 99.1 EXHIBIT A JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Class A common shares, par value $0.001 per share, of Enfusion, Inc. (this “Agreement”), is bei |
|
| February 14, 2022 |
SC 13G 1 p22-0789sc13g.htm ENFUSION, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Enfusion, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 292812104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the approp |
|
| February 14, 2022 |
EX-99.1 2 ex334881.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1)(iii) of the Securities Exchange Act of 1934, as amended, each of the undersigned agree to the joint filing on behalf of each of them of the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Class A common stock, par value $0.001 per share, of Enfusion, Inc. This |
|
| February 14, 2022 |
EX-99.1 2 d293448dex991.htm EXHIBIT A EXHIBIT A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Class A Common Stock, par value $0.001 per share, of Enfusion, Inc. and further ag |
|
| February 14, 2022 |
ENFN / Enfusion Inc - Class A / Movchan Oleg - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) * Enfusion, Inc. (Name of Issuer) Class A common stock, par value $0.001 per share (Title of Class of Securities) 292812104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2022 |
ENFN / Enfusion Inc - Class A / Dragoneer Investment Group, LLC - SC 13G Passive Investment SC 13G 1 d293448dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * ENFUSION, INC. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 292812104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 14, 2022 |
ENFN / Enfusion Inc - Class A / FTV IV, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Enfusion, Inc. (Name of Issuer) Class A common stock, par value $0.001 per share (Title of Class of Securities) 292812104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the Appropriate Box to Designate the R |
|
| February 14, 2022 |
ENFN / Enfusion Inc - Class A / ICONIQ Strategic Partners V, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Enfusion, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 292812104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| December 3, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ENFUSION, INC. Enfusion, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1.The name of the Corporation is Enfusion, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was June |
|
| December 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 3, 2021 |
EX-3.2 3 enfn-20210930xex3d2.htm EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ENFUSION, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1.Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors of |
|
| December 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 2, 2021 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40949 87-1268462 (State or other jurisdiction of Incorporation) (Commission File Nu |
|
| December 2, 2021 |
Enfusion Announces Third Quarter 2021 Results – Revenue Up 46.8% Year Over Year – EX-99.1 2 enfn-20211202xex99d1.htm EX-99.1 Exhibit 99.1 Enfusion Announces Third Quarter 2021 Results – Revenue Up 46.8% Year Over Year – December 2, 2021 NEW YORK & LONDON & HONG KONG-(BUSINESS WIRE)-Enfusion, Inc. (“Enfusion”), a leading provider of cloud-based investment management software and services, today announced financial results for the third quarter ended September 30, 2021. “We had a |
|
| October 22, 2021 |
18,750,000 Shares Enfusion, Inc. Class A common stock Table of Contents c Filed pursuant to Rule 424(b)(4) Registration No. 333-259635 18,750,000 Shares Enfusion, Inc. Class A common stock This is the initial public offering of Enfusion, Inc. We are offering 15,322,660 shares of our Class A common stock. The selling stockholders identified in this prospectus are offering 3,427,340 shares of Class A common stock. We will not receive any of the proceed |
|
| October 21, 2021 |
S-8 on October 20, 2021 (File No. 333-260398) S-8 1 tmb-20211020xs8.htm S-8 As filed with the U.S. Securities and Exchange Commission on October 20, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Enfusion, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation or Organ |
|
| October 20, 2021 |
8-A12B 1 tmb-20211020x8a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 87-1268462 (State or other jurisdiction of incorporation or organization) (I.R. |
|
| October 18, 2021 |
Enfusion, Inc. 125 South Clark Street, Suite 750 Chicago, IL 60603 Enfusion, Inc. 125 South Clark Street, Suite 750 Chicago, IL 60603 ? VIA EDGAR ? October 18, 2021 ? U.S. Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F Street, N.E. Washington, D.C. 20549 ? Attention: David Edgar Kathleen Collins Mitchell Austin Jan Woo ? ? ? Re: Enfusion, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-2 |
|
| October 18, 2021 |
October 18, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F Street, N.E. Washington, D.C. 20549 Attention: Mitchell Austin, Jan Woo David Edgar Kathleen Collins Re: Enfusion, Inc. Acceleration Request for Registration Statement on Form S-1 (File No. 333-259635) Ladies and Gentlemen: In connection with the above-captioned Registratio |
|
| October 15, 2021 |
October 15, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F Street, N.E. Washington, D.C. 20549 Attention: David Edgar Kathleen Collins Mitchell Austin Jan Woo Re: Enfusion, Inc. Amendment No. 2 to Registration Statement on Form S-1 Submitted October 12, 2021 CIK No. 0001868912 Ladies and Gentlemen: This letter is submitted on behal |
|
| October 15, 2021 |
Table of Contents c As filed with the Securities and Exchange Commission on October 15, 2021. |
|
| October 12, 2021 |
EX-10.4 11 tmb-20211004xex10d4.htm EX-10 Exhibit 10.4 ENFUSION, INC. 2021 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Enfusion, Inc. 2021 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Enfusion, Inc. (the “Company”) |
|
| October 12, 2021 |
Exhibit 10.15 SENIOR SECURED CREDIT FACILITIES AMENDED AND RESTATED CREDIT AGREEMENT dated as of October [], 2021, among ENFUSION, INC., as Holdings, ENFUSION LTD. LLC, as Borrower, THE SEVERAL LENDERS FROM TIME TO TIME PARTY HERETO, and SILICON VALLEY BANK, as Administrative Agent, Issuing Lender and Sole Lead Arranger CITY NATIONAL BANK, as Syndication Agent and CADENCE BANK, N.A., as Documentat |
|
| October 12, 2021 |
Form of Registration Rights Agreement. Exhibit 4.2 ENFUSION, INC. REGISTRATION RIGHTS AGREEMENT [DATE], 2021 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of the [•] day of [•], 2021, by and among Enfusion, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”. RECITALS WHEREAS, |
|
| October 12, 2021 |
Exhibit 10.6 SENIOR SECURED CREDIT FACILITIES CREDIT AGREEMENT dated as of August 2, 2019, among ENFUSION LTD. LLC, as Borrower, THE SEVERAL LENDERS FROM TIME TO TIME PARTY HERETO, and SILICON VALLEY BANK, as Administrative Agent and Issuing Lender Table of Contents Page SECTION 1 DEFINITIONS 1 1.1 Defined Terms 1 1.2 Other Definitional Provisions 36 1.3 Rounding 37 SECTION 2 AMOUNT AND TERMS OF C |
|
| October 12, 2021 |
Form of Amended and Restated Operating Agreement of Enfusion Ltd. LLC. Exhibit 10.2 ENFUSION LTD. LLC SEVENTH AMENDED AND RESTATED OPERATING AGREEMENT Dated as of [], 2021 THE UNITS REPRESENTED BY THIS SEVENTH AMENDED AND RESTATED OPERATING AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY OTHER APPLICABLE SECURITIES LAWS. SUCH UNITS MAY NOT BE SOLD, ASSIGNED, PLEDGED OR OTHERWISE DISPOSED OF AT ANY TIME WITHO |
|
| October 12, 2021 |
Exhibit 10.5 ? ENFUSION, INC. 2021 STOCK PURCHASE PLAN The name of the plan is the Enfusion, Inc. 2021 Stock Purchase Plan (the ?Plan?). The purpose of the Plan is to provide eligible employees of Enfusion, Inc. (the ?Company?) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company?s Class A common stock, par value $0.001 per share (the ?Comm |
|
| October 12, 2021 |
Form of Amended and Restated Bylaws of the Registrant. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ENFUSION, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1.Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors of the Corporation (the ?Board of Directors |
|
| October 12, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 [] Shares ENFUSION, INC. CLASS A COMMON STOCK (PAR VALUE $0.001 PER SHARE) UNDERWRITING AGREEMENT [], 2021 [·], 2021 Morgan Stanley & Co. LLC Goldman Sachs & Co. LLC as Representatives of the several Underwriters listed in Schedule I hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Goldman Sachs & Co. LLC 200 West Street New York, New York, 10282 Ladies an |
|
| October 12, 2021 |
EX-4.1 5 tmb-20211004xex4d1.htm EX-4.1 Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# . CLASS A COMMON STOCK PAR VALUE $0.001 CLASS A COMMON STOCK Certificate Number ZQ00000000 Shares * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * |
|
| October 12, 2021 |
Form of Tax Receivable Agreement. Exhibit 10.3 TAX RECEIVABLE AGREEMENT between ENFUSION, INC. and THE PERSONS NAMED HEREIN Dated as of [], 2021 TABLE OF CONTENTS Page Article I DEFINITIONS 2 SECTION 1.1. Definitions 2 Article II DETERMINATION OF CERTAIN REALIZED TAX BENEFIT 11 SECTION 2.1. Basis Schedule 11 SECTION 2.2. Tax Benefit Schedule 11 SECTION 2.3. Procedures, Amendments 12 Article III TAX BENEFIT PAYMENTS 13 SECTION 3.1. |
|
| October 12, 2021 |
Non-Employee Director Compensation Policy. Exhibit 10.7 Enfusion, Inc. Non-Employee Director Compensation Policy The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Enfusion, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its su |
|
| October 12, 2021 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES ? ? ? Subsidiary Jurisdiction of Organization Enfusion Ltd. LLC ? Delaware ? |
|
| October 12, 2021 |
As filed with the Securities and Exchange Commission on October 12, 2021. Table of Contents ? ? As filed with the Securities and Exchange Commission on October 12, 2021. |
|
| October 12, 2021 |
Form of Amended and Restated Certificate of Incorporation of the Registrant. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ENFUSION, INC. Enfusion, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1.The name of the Corporation is Enfusion, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was June |
|
| October 12, 2021 |
EX-10.1 8 tmb-20211004xex10d1.htm EX-10.1 Exhibit 10.1 ENFUSION, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of by and between Enfusion, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company; WHEREA |
|
| September 28, 2021 |
Exhibit 10.14 ? Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. ? ? OFFICE LEASE ? BY AND BETWEEN ? 125 S. CLARK (CHICAGO) SPE, LLC, A DELAWARE LIMITED LIABILITY COMP |
|
| September 28, 2021 |
September 28, 2021 Via EDGAR and Overnight Delivery U.S. Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F Street, N.E. Washington, D.C. 20549 Attention: David Edgar Kathleen Collins Mitchell Austin Jan Woo Re: Enfusion, Inc. Registration Statement on Form S-1 Submitted September 17, 2021 CIK No. 0001868912 Ladies and Gentlemen: This letter is submitted |
|
| September 28, 2021 |
As filed with the Securities and Exchange Commission on September 28, 2021. Table of Contents ? ? As filed with the Securities and Exchange Commission on September 28, 2021. |
|
| September 17, 2021 |
September 17, 2021 Via EDGAR and Overnight Delivery U.S. Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F Street, N.E. Washington, D.C. 20549 Attention: David Edgar Kathleen Collins Mitchell Austin Jan Woo Re: Enfusion, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted August 18, 2021 CIK No. 0001868912 Ladies and Gentlemen: Thi |
|
| September 17, 2021 |
Employment Agreement, dated February 1, 2021, by and between Enfusion Ltd. LLC and Tarek Hammoud. Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| September 17, 2021 |
Employment Agreement, dated February 1, 2021, by and between Enfusion Ltd. LLC and Thomas Kim. Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| September 17, 2021 |
publicly filed with the Commission on September 17, 2021 Table of Contents ? ? As filed with the Securities and Exchange Commission on September 17, 2021. |
